BR112022003149A2 - Lurbinectedina no tratamento de mesotelioma maligno - Google Patents

Lurbinectedina no tratamento de mesotelioma maligno

Info

Publication number
BR112022003149A2
BR112022003149A2 BR112022003149A BR112022003149A BR112022003149A2 BR 112022003149 A2 BR112022003149 A2 BR 112022003149A2 BR 112022003149 A BR112022003149 A BR 112022003149A BR 112022003149 A BR112022003149 A BR 112022003149A BR 112022003149 A2 BR112022003149 A2 BR 112022003149A2
Authority
BR
Brazil
Prior art keywords
lurbinectedin
treatment
malignant mesothelioma
mesothelioma
malignant
Prior art date
Application number
BR112022003149A
Other languages
English (en)
Inventor
Ioannis Metaxas
Von Moos Roger
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR112022003149A2 publication Critical patent/BR112022003149A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

lurbinectedina no tratamento de mesotelioma maligno. a presente invenção refere-se ao uso de lurbinectedina no tratamento de mesotelioma maligno é fornecido.
BR112022003149A 2019-09-03 2020-09-03 Lurbinectedina no tratamento de mesotelioma maligno BR112022003149A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19382749 2019-09-03
PCT/EP2020/074689 WO2021043949A1 (en) 2019-09-03 2020-09-03 Lurbinectedin in the treatment of malignant mesothelioma

Publications (1)

Publication Number Publication Date
BR112022003149A2 true BR112022003149A2 (pt) 2022-05-17

Family

ID=67902455

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003149A BR112022003149A2 (pt) 2019-09-03 2020-09-03 Lurbinectedina no tratamento de mesotelioma maligno

Country Status (13)

Country Link
US (1) US20230241041A1 (pt)
EP (1) EP4025217A1 (pt)
JP (1) JP2022547049A (pt)
KR (1) KR20220054872A (pt)
CN (1) CN114423429A (pt)
AU (1) AU2020342483A1 (pt)
BR (1) BR112022003149A2 (pt)
CA (1) CA3148690A1 (pt)
CL (1) CL2022000522A1 (pt)
IL (1) IL290656A (pt)
MX (1) MX2022002699A (pt)
TW (1) TW202116783A (pt)
WO (1) WO2021043949A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022048775A1 (en) * 2020-09-04 2022-03-10 Pharma Mar, S.A. Combination of lurbinectedin and immune checkpoint inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
CN106974902A (zh) * 2016-01-18 2017-07-25 贵州益佰制药股份有限公司 洛铂在制备治疗恶性胸膜间皮瘤药物中的应用

Also Published As

Publication number Publication date
KR20220054872A (ko) 2022-05-03
AU2020342483A1 (en) 2022-04-14
MX2022002699A (es) 2022-04-11
EP4025217A1 (en) 2022-07-13
CN114423429A (zh) 2022-04-29
JP2022547049A (ja) 2022-11-10
WO2021043949A1 (en) 2021-03-11
TW202116783A (zh) 2021-05-01
IL290656A (en) 2022-04-01
US20230241041A1 (en) 2023-08-03
CA3148690A1 (en) 2021-03-11
CL2022000522A1 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
EP4302835A3 (en) Methods of treating ovarian cancer
TWD167898S (zh) 手鏈
AU357154S (en) Hand shower
BR112016007891A2 (pt) uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer
BR112016022667A2 (pt) Uso de álcool d-pantotenílico para a fabricação de inibidor de melanogênese e método de branquear a pele
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
PH12019500725A1 (en) Methods of treating acute kidney injury
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
TWD196373S (zh) 過濾器附載之感應器外殼
MX2018010709A (es) Terapia del cancer con un virus oncolitico combinado con un inhibidor de punto de control.
BR112021011124A2 (pt) Anelossomos e métodos de uso
BR112022003149A2 (pt) Lurbinectedina no tratamento de mesotelioma maligno
BR112019018028A2 (pt) Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BR112017020408A2 (pt) ?biotinas e composições?
CO2017003067A2 (es) Compuestos de dipeptidil-cetoamida
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
BR112016028081A2 (pt) Novos compostos como agentes antituberculares
WO2018183494A8 (en) CONJUGATES ANTIBODY-DRUG TARGETED CD19
TWD191502S (zh) 淨水器
TWD191501S (zh) 淨水器